Beloranib

Drug Profile

Beloranib

Alternative Names: 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate; Beloranib hemioxalate; CKD-732; TNP-470 analogue; ZGN-433; ZGN-440

Latest Information Update: 02 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; Zafgen
  • Class Antineoplastics; Cyclohexanes; Obesity therapies; Sesquiterpenes; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Neuroectodermal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Obesity; Prader-Willi syndrome; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Jul 2016 Discontinued - Phase-I for Colorectal cancer (Combination therapy) in South Korea (IV)
  • 19 Jul 2016 Discontinued - Phase-I for Solid tumours in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top